Market Snapshot

BSE Sensex: 85267.66 0.53%
BSE 500: 37228.82 0.72%
BSE 200: 11752.7 0.68%
BSE 100: 27246.8 0.61%
BSE MidCap: 46477.51 1.14%
BSE SmallCap: 50890.67 0.65%
BSE BANKEX: 66662.68 0.30%
BSE IT: 37004.68 0.45%
Nifty 50: 26046.95 0.57%
Nifty 500: 23726.2 0.74%
Nifty 200: 14469.3 0.72%
Nifty 100: 26565.1 0.62%
Nifty Midcap 100: 60283.3 1.18%
Nifty Small 100: 17389.95 0.94%
Nifty IT: 38274.75 0.47%
Nifty PSU Bank: 8247.8 0.15%

News:

United Drilling Tools secures ...
Biocon?s arm inks pact to comm...
GPT Infraprojects secures Rs 5...
KEC International bags Rs 1,15...
Astra Microwave Products bags ...

Zim Laboratories Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

12 Dec 2025 | 03:59 PM

73.59

-1.34 (-1.79%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-35.28%

Return (1Y)

Underperformed BSE Sensex by 40.17%
More Volatile

3.07%

Standard Deviation (1Y)

Higher than BSE Sensex by 2.32%
Not so consistent

4/12

Months

underperformed BSE Sensex
AxisDirect View

No View

52 Week High-Low

127

News & Announcements

Zim Laboratories gets CDSCO nod for Naproxen?Esomeprazole combination capsule
10 days ago

Zim Laboratories gets CDSCO nod for Naproxen?Esomeprazole combination capsule

03 - Dec - 2025 12:00 | 10 days ago

The formulation has been developed using the company?s proprietary drug delivery technologies, combining naproxen delayed-release minitablets and esomeprazole pellets in a single hard gelatin capsule. Zim said the platform offers a differentiated, patient-friendly delivery system and forms part of its New Innovative Product (NIP) pipeline.
The FDC is indicated for adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for reducing the risk of NSAID-associated gastric and duodenal ulcers.
Zim Laboratories stated that the approval strengthens its presence in the pain-management and gastro-protective segments. The company has already signed a commercial supply agreement with an Indian pharmaceutical firm and is working toward launching the product in India in FY 2026?27 (FY27). Zim added that the approval aligns with its strategy of developing innovative, differentiated generics using advanced formulation technologies.
ZIM Laboratories is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.
The company's consolidated net profit dropped 117.6% to Rs 0.42 crore as revenue fell 3.7% to Rs 88.71 crore in the quarter ended September 2025 as compared with the previous quarter ended September 2024.
The scrip rose 0.45% to Rs 71.15 on the BSE.
Powered by Capital Market - Live News
Zim Laboratories reports consolidated net loss of Rs 0.42 crore in the September 2025 quarter
30 days ago

Zim Laboratories reports consolidated net loss of Rs 0.42 crore in the September 2025 quarter

13 - Nov - 2025 12:00 | 30 days ago

Net loss of Zim Laboratories reported to Rs 0.42 crore in the quarter ended September 2025 as against net profit of Rs 2.38 crore during the previous quarter ended September 2024. Sales declined 3.72% to Rs 88.71 crore in the quarter ended September 2025 as against Rs 92.14 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 88.71 92.14 -4

OPM % 6.49 10.34 -

PBDT 4.64 7.96 -42

PBT -0.34 2.96 PL

NP -0.42 2.38 PL

Powered by Capital Market - Live News
Zim Laboratories to hold board meeting
37 days ago

Zim Laboratories to hold board meeting

06 - Nov - 2025 12:00 | 37 days ago

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 12 November 2025.
Powered by Capital Market - Live News
Zim Laboratories reports consolidated net loss of Rs 1.87 crore in the June 2025 quarter
127 days ago

Zim Laboratories reports consolidated net loss of Rs 1.87 crore in the June 2025 quarter

08 - Aug - 2025 12:00 | 127 days ago

Net loss of Zim Laboratories reported to Rs 1.87 crore in the quarter ended June 2025 as against net profit of Rs 0.90 crore during the previous quarter ended June 2024. Sales declined 12.30% to Rs 71.76 crore in the quarter ended June 2025 as against Rs 81.82 crore during the previous quarter ended June 2024.

Particulars Quarter Ended
Jun. 2025 Jun. 2024 % Var.

Sales 71.76 81.82 -12

OPM % 5.94 9.83 -

PBDT 2.43 6.18 -61

PBT -2.43 1.23 PL

NP -1.87 0.90 PL

Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Zim Laboratories Ltd has decreased by -100% since past 3 Months
FII shareholding in Zim Laboratories Ltd has decreased by -100% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	88.71	92.14	-4
OPM %	6.49	10.34	-
PBDT	4.64	7.96	-42
PBT	-0.34	2.96	PL
NP	-0.42	2.38	PL

Particulars	Quarter Ended
	Jun. 2025	Jun. 2024	% Var.
Sales	71.76	81.82	-12
OPM %	5.94	9.83	-
PBDT	2.43	6.18	-61
PBT	-2.43	1.23	PL
NP	-1.87	0.90	PL

General Notifications

My Notifications

Research Notifications

Zim Laboratories Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

73.59 -1.34 (-1.79%)

News & Announcements

Price vs Volume

Stock Trivia

Zim Laboratories Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

73.59

-1.34 (-1.79%)